# US 10,308,990 B2 · Methods of evaluating a cellular sample for latent cellular replication competent HIV-1 > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,308,990 B2 - Document ID: US10308990B2 - Status: Granted - Kind: B2 - Application number: 14/807,817 - Filed: 2015-07-23 - Published: 2016-01-28 - Granted: 2019-06-04 - Earliest claimed: 2014-07-25 - Assignees: IncellDx, Inc. - Applicants: IncellDx, Inc. - Inventors: Bruce K. Patterson; Amanda Noel Chargin; Fangfang Yin; Min Song; Srividyabhuvaneswari Subramaniam; Grace Elaine Knutson - Web page: https://patentgrep.com/patent/US10308990B2 ## CPC - C12Q 1/703: {Viruses associated with AIDS} - C12M 23/08: {Flask, bottle or test tube} - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS} ## Abstract Methods of evaluating a cellular sample for latent cellular replication competent HIV-1 are provided. Aspects of the methods include contacting a cellular sample with an HIV-1 inducing compound to produce an activated cellular sample; and assessing plasma viral load in the activated cellular sample to evaluate the cellular sample for latent cellular replication competent HIV-1. Also provided are devices and kits that find use in practicing the methods. ## Claims ### Claim 1 A method of evaluating a cellular sample for latent cellular replication competent HIV-1, the method comprising: activating a whole blood sample, the activating consisting essentially of contacting the whole blood sample with an HIV-1 inducing compound consisting essentially of a lectin to produce an activated cellular sample, wherein the whole blood sample is not contacted with culture medium; and assessing plasma viral load in the activated cellular sample to evaluate the cellular sample for latent cellular replication competent HIV-1. ### Claim 2 (depends on 1) The method according to claim 1, wherein the evaluating comprises evaluating latent cellular replication competent HIV-1 from PBMCs. ### Claim 3 (depends on 1) The method according to claim 1, wherein the evaluating comprises determining the presence of latent cellular replication competent HIV-1. ### Claim 4 (depends on 1) The method according to claim 1, wherein the lectin comprises a phytohemagglutinin. ### Claim 5 (depends on 1) The method according to claim 1, wherein assessing plasma viral load comprises employing a nucleic acid mediated protocol. ### Claim 6 (depends on 5) The method according to claim 5, wherein the nucleic acid mediated protocol comprises a real-time PCR protocol. ### Claim 7 (depends on 1) The method according to claim 1, wherein the method further comprises genotyping identified latent cellular replication competent HIV-1. ### Claim 8 (depends on 1) The method according to claim 1, wherein the method further comprises producing a HIV-1 therapeutic regimen based on the evaluation. ### Claim 9 (depends on 1) The method according to claim 1, wherein the method further comprises assessing the effectiveness of a HIV-1 therapeutic regimen based on the evaluation. ### Claim 10 (depends on 1) The method according to claim 1, wherein the method further comprises obtaining the cellular sample from a living subject. ### Claim 11 (depends on 1) The method according to claim 1, wherein the contacting consists essentially of placing the blood sample into a container comprising the HIV-1 inducing compound. ### Claim 12 (depends on 11) The method according to claim 11, wherein the HIV-1 inducing compound is coated on an interior surface of the container. ### Claim 13 (depends on 11) The method according to claim 11, wherein the blood sample is collected from a living subject into the container. ### Claim 14 (depends on 1) The method according to claim 1, wherein the HIV-1 inducing compound consists of a lectin. ### Claim 15 (depends on 14) The method according to claim 14, wherein the lectin is phytohemagglutinin. ### Claim 16 (depends on 1) The method according to claim 1, wherein the activating consists of contacting the whole blood sample with the HIV-1 inducing compound. ### Claim 17 (depends on 1) The method according to claim 1, wherein the activating comprises incubating the whole blood sample with the HIV-1 inducing compound for a period of 12 hours to 96 hours to produce the activated cellular sample. ### Claim 18 (depends on 17) The method according to claim 17, wherein the period is 24 hours to 72 hours. ### Claim 19 (depends on 4) The method according to claim 4, wherein assessing plasma viral load comprises employing a nucleic acid mediated protocol. ### Claim 20 (depends on 19) The method according to claim 19, wherein the activating comprises incubating the whole blood sample with the HIV-1 inducing compound for a period of 24 hours to 72 hours to produce the activated cellular sample. ### Claim 21 (depends on 20) The method according to claim 20, wherein the nucleic acid mediated protocol comprises a real-time PCR protocol.